Clinical trials
Phase 3 Glucose Metabolism Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2003 | 6 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 10 |
| 2007 | 6 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Terminated | 10 |
| Active, not recruiting | 4 |
| Recruiting | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Takeda | 27 |
| Eli Lilly and Company | 9 |
| AstraZeneca | 5 |
| Solvay Pharmaceuticals | 3 |
| Merck Sharp & Dohme LLC | 2 |
| Pfizer | 2 |
| Daewoong Pharmaceutical Co. LTD. | 1 |
| Denver Health and Hospital Authority | 1 |
| Gerstein, Hertzel, MD | 1 |
| Hvidovre University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glucose Metabolism Disorders | 57 |
| Diabetes Mellitus, Type 2 | 48 |
| Diabetes Mellitus | 47 |
| Dyslipidemias | 29 |
| Metabolic Diseases | 25 |
| Endocrine System Diseases | 22 |
| Diabetes Mellitus, Lipoatrophic | 16 |
| Body Weight | 3 |
| Cardiovascular Diseases | 3 |
| Nutrition Disorders | 3 |
Trials
Showing 51 to 57 of 57. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.